How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,770 results for

Cerebral Aneurysm

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5421. tDCS in Parkinson's Disease With Depression

or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes, or developmental disorder, have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any (...) other metal object within or near the head, excluding the mouth, that cannot be safely removed, are taking a non-SSRI antidepressant medication, are pregnant (women of childbearing age only). Exclusion Criteria for PET: unable to tolerate staying off anti-parkinsonian medication for 12-18 hours pre-PET scan, have a history of radiation therapy treatment or other high amounts of radiation. Exclusion Criteria for MRI: Artificial heart valve; Brain aneurysm clip; Electrical stimulator for nerves

2014 Clinical Trials

5422. Interrater Reliability of Subjective Pupillary Assessments

identified and pupil dilation has been incorporated into standard of care (e.g., TBI, stroke). Criteria Inclusion Criteria: Patients are eligible for this study if they have been diagnosed with some form of brain trauma (e.g., stroke, traumatic brain injury, aneurysm) Exclusion Criteria: Prisoners Under 18 years of age Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible Party: DaiWai Olson, Associate Faculty, University (...) a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Probability Sample Study Population Patients eligible for the study are those that have been diagnosed some form of brain trauma where brain swelling has been

2014 Clinical Trials

5423. Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease

angiographic features :lesion/anatomy related bifurcation lesion, left main lesion, multiple vessel disease, intracoronary thrombus, SYNTAX score > 26 and chronic total occlusion disease. Exclusion Criteria: Increased bleeding risk: ischaemic stroke within the last year or any previous haemorrhagic stroke, tumour or intracranial aneurysm; Recent (<1 month) trauma or major surgery (including bypass surgery); Active bleeding Unexplained clinically significant bleeding, thrombocytopenia (platelet count < 100 (...) cardiac and cerebral events (MACCE) [ Time Frame: 30 days and 1 year ] a composite of all cause death, reinfarction, target vessel revascularization or stroke stent thrombosis [ Time Frame: 30 days and 1 year ] by ARC definition Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your

2014 Clinical Trials

5424. Dabigatran Following Transient Ischemic Attack and Minor Stroke

arteriovenous malformations, intracranial aneurysms, tumors or abscess, which potentially increase the rise of bleed. Individuals with small incidental leasions, at low risk of bleed such as meningiomas may be included at the discretion of the investigator. Patients with an acute DWI lesion volume of >25 ml (DWI volume to be estimated using the ABC/2 technique 110)** Age <18 years Pregnant or breast feeding women. Severe dysphagia necessitating naso-gastric (NG) feeding (dabigatran can not be delivered via (...) Study Details Study Description Go to Brief Summary: Rationale: To date, anticoagulant therapy in acute stroke has also been limited by excess hemorrhagic events. The oral anticoagulant dabigatran is a novel agent, which has been shown to be associated with much lower intracranial hemorrhage rates. It has been suggested that this agent may provide the superior benefits of anticoagulation in acute stroke, without the concomitant increase in hemorrhage risk associated with heparin/LMWH or warfarin

2014 Clinical Trials

5425. Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma

; history of stroke, cerebral vascular accident or transient ischemic attack within 6 months; serious and inadequately controlled cardiac arrhythmia; significant vascular disease (e.g.;, high risk aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease; evidence of bleeding diathesis or coagulopathy; serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess, major surgical (...) : Prior chemotherapy, surgical therapy, or radiotherapy for IHC. Patients who are receiving any other investigational agents or have been treated with any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study. Patients with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other

2014 Clinical Trials

5426. A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain

within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurism or CNS mass lesion. History of congenital bleeding diathesis or any active clinically significant bleeding or underlying platelet dysfunction. Gastrointestinal bleeding that required medical intervention. Platelet count less than 80.000 determined within the 28 days prior to surgery. Pre-existing dependence on narcotics or receiving chronic treatment with opioids. Severe renal failure (...) within 12 hours prior to the first planned dose. Taking oral anticoagulants, lithium, combination of ACE inhibitors, furosemide or aspirin. Anaemia (haemoglobin <10 g/dl) and/or history or evidence of asthma or heart failure. History of allergy or hypersensitivity to any component of IV ibuprofen, aspirin or aspirin related products, NSAID or COX-2 inhibitors. Pregnant or nursing. Weight less than 40 kg. History of severe head trauma that required hospitalization, intracranial surgery or stroke

2014 Clinical Trials

5427. Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with hemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, Central nervous system (CNS) trauma, retinopathy, nephrolithiasis) Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of CNS or eye or surgery resulting in large open

2014 Clinical Trials

5428. Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, CNS trauma, retinopathy, nephrolithiasis) Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of central nervous system (CNS) or eye or surgery resulting in large open surfaces) within 14 days before (...) considered by the investigator or one of the co-investigators to be clinically relevant Hemoglobin concentration <9 mg/dl Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta,CNS trauma, retinopathy, nephrolithiasis) considered

2014 Clinical Trials

5429. PET Imaging in ALS Patients

: This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and monitoring progression of ALS, based on a well established basic science pathway, published human autopsy data, preliminary data in ALS mutant mice, and our recently published data using brain PET scans to image the metabotropic glutamate receptor type 5 (mGluR5) in healthy human volunteers. Condition or disease Intervention/treatment Phase Amyotrophic Lateral Sclerosis (ALS) Other: PET Scanning Not Applicable Study (...) in at least two extremities. Forced vital capacity less than 80% and greater than 50%. Exclusion Criteria: Documented orthopnea or otherwise unable to lie flat in a PET scanner for 90 minutes. Presence of pacemakers, aneurysm clips, shrapnel, or other implanted metallic devices that would preclude an MRI scan. Absence of sufficient collateral arterial circulation for radial arterial line placement in both wrists. Significant abnormalities of hepatic or renal function, or illicit substance use. Positive

2014 Clinical Trials

5430. Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

of AT (history of intra-cerebral bleed, presence of intra-cerebral mass, recent or <6 weeks gastrointestinal bleed, blood transfusion within the last 6 weeks, any trauma requiring surgery or blood transfusion within the last 4 weeks or any surgical procedure within the last 4 weeks. Angiographic: Endovascular intervention to iliac, femoropopliteal or BTK artery bypass graft Persistent, intraluminal thrombus of the proposed target lesion at the completion of the index procedure Perforated vessel as evidenced (...) by extravasation of contrast media Vascular graft, aneurysm or postsurgical stenosis of the target vessel Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02217501 Contacts Layout table for location contacts Contact: Ishita Tejani, BDS,MS, MSPH 2148573048

2014 Clinical Trials

5431. Psychosis and Affective Research Domains and Intermediate Phenotypes

., artificial joints, brain aneurism clips, surgical pins, rods, wires, implants) or non-medical (e.g., metal piercing) irremovable metallic objects on/inside body (due to MRI-relevant risks) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02218853 (...) ('classical' endophenotypes). We then estimated the number of subgroups that efficiently optimized variance among the biomarkers (n=3) and differentiated the individual psychosis cases into these subgroups. Subsequently, the subgroups were tested for biological uniqueness using meaningful external validators (structural and functional brain imaging, social functioning, and familial data). Given the neurobiological distinctiveness of these subgroups, we called them psychosis Biotypes. DSM diagnoses were

2014 Clinical Trials

5432. Drug-coated Balloon Versus Drug-eluting Stent in Acute Myocardial Infarction

before inclusion. Exclusion Criteria: Age < 18 years and > 75 years History of myocardial infarction Known contraindication/resistance for bivalirudin, fondaparinux, heparin, aspirin, prasugrel and/or ticagrelor. Participation in another clinical study, interfering with this protocol Uncertain neurological outcome e.g. resuscitation Intubation/ventilation Cardiogenic shock prior to randomization Known intracranial disease (mass, aneurysm, AVM, hemorrhagic CVA, ischemic CVA/TIA < 6 months prior (...) -segment resolution post-initial procedure at 90 minutes, defined as the ST-segment deviation resolution in only the single lead showing maximum deviation. Non-coronary artery bypass grafting major bleeding [ Time Frame: At 1 month follow-up ] Intracranial, intraocular, intra-articular or retroperitoneal bleeding Access site bleed requiring intervention/surgery Hematoma ≥ 5 cm Hemoglobin (Hgb) ≥4 g/dL without an overt source Hgb ≥3 g/dL with an overt source Operation for bleeding Any blood transfusions

2014 Clinical Trials

5433. Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

or interpretation of the results or who in the opinion of the investigator are not suitable to participate. Subjects with Alpha-1 antitrypsin deficiency (an inherited disorder that can cause lung disease and liver disease). Unwilling and/or not able to give written consent Patient is positive for hepatitis (past history of Hepatitis A is allowed) Any medical condition, which in the opinion of the clinical investigator, would interfere with the treatment or outcome of the patient Cerebral aneurysm clips Contacts

2014 Clinical Trials

5434. Thrombolysis in Ischemic Spinal Cord Stroke

: Ischemic stroke of the spinal cord is a rare disease accounting for about 1% of all ischemic events in the central nervous system (CNS). In most cases the consequences are catastrophic, with a high rate of severe functional disability and mortality rate up to 30%. Ischemic stroke of the spinal cord can arise from: Dissection of the aorta. Aneurism in the aorta. Atherosclerotic disease of the aorta or vertebral arteries. Spinal surgeries. Spinal AVM. Embolism from cardiac origin. Occlusion of radicular (...) or acute demyelinating polyneuropathy like Guillan Barree Syndrome (GBS). Therefore in order to reach the appropriate diagnosis in most cases an urgent MRI of the spinal cord is necessary upon arrival in the emergency department. One of the treatments to acute ischemic stroke is providing thrombolysis. As tested and validated in numerous studies for ischemic events in the brain, until today no validated study in ischemic spinal stroke using thrombolysis has been completed. Condition or disease

2014 Clinical Trials

5435. Safety Evaluation of 3K3A-APC in Ischemic Stroke

puncture time < 6 hours Exclusion Criteria: History of stroke or penetrating head injury within 90 days prior to enrollment History of previous or current diagnosis of intracranial hemorrhage that represents a potential for re-hemorrhage if subjected to thrombolytic therapy or mechanical thrombectomy Moyamoya disease, cerebral arterio-venous malformation (AVM), known unsecured aneurysm requiring intervention during the acute study period Presence of other neurological or non-neurological co-morbidities (...) Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by ZZ Biotech, LLC: ischemic stroke stroke APC 3K3A 3K3A-APC activated protein C RHAPSODY Additional relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases

2014 Clinical Trials

5436. Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

, traumatic brain injury, substance abuse, malignancy Clinically significant laboratory or ECG abnormality MRI indicative of any other significant abnormality, including but not limited to evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions Any condition that would contraindicate an MRI such as the presence of metallic objects in the eyes, skin, heart, or body Contacts and Locations Go to Information from the National Library (...) Collaborator: National Institute on Aging (NIA) Information provided by (Responsible Party): Roberta Brinton, University of Southern California Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants. The primary goal is to determine the maximally tolerated dose. Condition or disease Intervention/treatment Phase

2014 Clinical Trials

5437. OCT Study of the MGuard Prime Stent in Patients With Heart Attacks

6 months, or any permanent neurologic deficit Prior intracranial bleed at any time, or known intracranial pathology (e.g. tumor, arteriovenous malformation, or aneurysm). Active or recent major bleeding within 6 months. History of bleeding diathesis or coagulopathy or inability to accept blood transfusions. Known hypersensitivity or contraindication to i) aspirin; or ii) heparin and bivalirudin; or iii) clopidogrel, prasugrel and ticagrelor; or iv) cobalt or nickel; or v) contrast media, which

2014 Clinical Trials

5438. ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

History of intracranial hemorrhage History of multiple strokes, or a stroke within past 6 months Subjects with a history of seizures within the past year Subjects with brain tumors Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment Are participating or have participated in another clinical trial in the last 30 days Any illness that in the investigator's opinion preclude participation in this study Subjects unable to communicate (...) contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 30 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Men and women, age 30 years and older Subjects who are able and willing to give informed consent and able to attend all study visits Subjects with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed

2014 Clinical Trials

5439. The Effect of Phenylephrine and Ephedrine on Microvascular Blood Flow

: previous stroke, aneurysm (large vessel or intracranial) Peripheral vascular disease Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes Active inflammatory bowel disease, or renal disease Known prostatic hypertrophy Malignancy Clotting dysfunction Previous oesophageal surgery Individuals with a known history of oesophageal varices Individuals with a known history of epistaxis Family history of early (<55y) death from

2014 Clinical Trials

5440. Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

and Stroke (NINDS) Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ) Study Details Study Description Go to Brief Summary: OBJECTIVES: Deficits in memory, attention, cognitive, and executive functions are the most common disabilities after traumatic brain injury (TBI). Dopamine (DA) neurotransmission is implicated in these neural functions and dopaminergic pathways are recognized (...) methylphenidate. STUDY POPULATION: Males and females (n=30), between the ages of 18 and 55 years in the chronic stage after TBI who experience deficits in neuropsychological function from TBIs incurred 6 months after the injury, will be recruited from military treatment facilities or civilian clinics when presenting for clinical management of TBI or postconcussive symptoms. DESIGN: Study participants will be evaluated using brain MRI, psychometric measures adapted from the TBI Common Data Elements, attention

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>